1. Prophylactic vaccine delivery systems against epidemic infectious diseases
- Author
-
Heng-liang Wang, Li Zhu, Guanghui Ma, Chao Pan, and Hua Yue
- Subjects
STING, Stimulator of interferon genes ,CRKP, Carbapenem-resistant K. pneumoniae ,CS-TPP, Chitosan-tripolyphosphate ,Pharmaceutical Science ,CPTEG:CPH, 1,8-bis(p-carboxyphenoxy)−3,6-dioxaoctane: 1,6-bis(p-carboxyphenoxy)hexane ,LTA, Heat-labile enterotoxin A subunit ,Drug Delivery Systems ,CSP, Circumsporozoite protein ,Long-term ,MSNs, magnetic mesoporous silica nanoparticles ,Still face ,HBV, Hepatitis B virus ,HTCC, N-(2-hydroxy)-propyl-3-trimethyl ammonium chitosan chloride ,Hib, Haemophilus influenzae type b ,SEM, Scanning electron microscopy ,cCHP, Cholesteryl group-bearing pullulan ,aPVs, Acellular pertussis vaccines ,FUC, Fucoidan ,CFs, Colonization factors ,CTB, Cholera toxin B subunit ,Immunogenicity ,PLGA, Polylactic-co-glycolic acid ,CTL, Cytotoxic T cell ,DC, Dendritic cells ,PS-GAMP, Pulmonary surfactant-biomimetic liposomes ,ETEC, Enterotoxigenic E. coli ,HPV, Human papillomavirus ,SBA-15, Santa Barbara Amorphous-15 ,PA, Protective antigen ,PLA, Poly (lactic acid) ,HIV, Human immunodeficiency virus ,BN-OMVs, Bovine serum albumin nanoparticles ,GM1, Monosialotetrahexosylganglioside ,LDH, 1,8-bis(p-carboxyphenoxy)−3,6-dioxaoctane: Hydroxide ,MN, Microneedle ,Cross-protection ,High efficiency ,TLR, Toll-like receptor ,VLPs, Virus-like particles ,NF, Nanofibrous membrane ,stx, Shiga toxin ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,NP/NCMP, Poly (glycerol adipate-co-ω-pentadecalactone) (PGA-co-PDL) polymeric nanoparticles (NPs) / L-leucine microcarriers (nanocomposite microparticles-ncmps) ,APCs, Antigen-presenting cells ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,ICG, indocyanine green ,RBD, Receptor binding domain ,N-IpaD, N-terminal region of IpaD ,STxA, Shiga toxin A subunit ,HR, Heptad repeat ,Communicable Diseases ,Article ,PDNVs, protoplast-derived nanovesicles ,GEM, Gram-positive enhancer matrix ,PM, Pulmonary ,Nano/micro vehicles ,PBAE, Poly (β-amino ester) ,TMC, Trimethyl chitosan ,medicine ,Animals ,Humans ,Subunit vaccines ,Epidemic pathogens ,HEC, Hectorite ,Intensive care medicine ,Epidemics ,PAD4, Domain 4 of PA ,PAPE, Pickering emulsion ,ComputingMethodologies_COMPUTERGRAPHICS ,EVs, Extracellular vesicles ,business.industry ,NMVs, Nano-multilamellar lipid vesicles ,LEPS, Liposomal encapsulation of polysaccharides ,COVID-19 ,LTB, Heat-labile enterotoxin B subunit ,TRM, Memory T cells ,Vaccine delivery ,PLG, Poly (lactid-co-glycolid) ,HUS, Hemolytic–uremic syndrome ,LPS, Lipopolysaccharides ,AVA, Anthrax vaccine absorbed ,Cu-Zn SOD, Cu-Zn superoxide dismutase ,Tfh, T-follicular helper ,RV, Rabies virus ,FHV, Flock house virus ,Liposomes ,wPV, whole-cell pertussis vaccine ,Nanoparticles ,Pre-Exposure Prophylaxis ,LOS, Lipooligosaccharide ,CaPNs, Calcium phosphate nanoparticles ,business ,CPS, Capsular polysaccharide ,OMVs, Outer membrane vesicles - Abstract
Graphical abstract, Prophylactic vaccines have evolved from traditional whole-cell vaccines to safer subunit vaccines. However, subunit vaccines still face problems, such as poor immunogenicity and low efficiency, while traditional adjuvants are usually unable to meet specific response needs. Advanced delivery vectors are important to overcome these barriers; they have favorable safety and effectiveness, tunable properties, precise location, and immunomodulatory capabilities. Nevertheless, there has been no systematic summary of the delivery systems to cover a wide range of infectious pathogens. We herein summarized and compared the delivery systems for major or epidemic infectious diseases caused by bacteria, viruses, fungi, and parasites. We also included the newly licensed vaccines (e.g., COVID-19 vaccines) and those close to licensure. Furthermore, we highlighted advanced delivery systems with high efficiency, cross-protection, or long-term protection against epidemic pathogens, and we put forward prospects and thoughts on the development of future prophylactic vaccines.
- Published
- 2021